Budesonide/formoterol as alternate day use versus daily use in the maintenance therapy stage of asthma in children: a multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017421

Enrollment

Unknown

Registered

2018-07-30

Start date

2018-10-01

Completion date

Unknown

Last updated

2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

experimental group:inhale budesonide/formoterol on alternate days

control group:inhale budesonide/formoterol every day

Eligibility

Sex/Gender

All

Age

7 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Outpatients who have received a clinical diagnosis of asthma according to Guidelines of Diagnosis and treatment of Childhood Asthma in China(2016); 2. Outpatients who have received the treatment of ICS/LABA for at least 3 months and were defined as controlled asthma according to asthma control test (ACT); 3. Patients 7-14 years of age who can inhale ICS/LABA and cooperate with the collection of clinical data are eligible 4. Volunteers.

Exclusion criteria

Exclusion criteria: 1. Concomitant with other respiratory diseases or other serious diseases, Mental Patients; 2. Patients with chronic sinusitis and third degree adenoid hypertrophy; 3. Atypical asthma.

Design outcomes

Primary

Measure	Time frame
the time and number of SABA usage;	—

Countries

China

Contacts

Public ContactJianxin Tan

Affiliated Hospital of Guangdong Medical University

tjx_erkexue@qq.com+86 13828201586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026